Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer
← catalyst calendarNCT07756034 · readout ≤ 1,807 d
Sponsored by Tempus AI (industry) · TEM — their whole pipeline →. With Blood Cancer United.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,000estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Aug 2026 | estimated | When the study began enrolling |
| Primary completion | Jul 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cancer
- Solid Tumor Cancer
- Pediatric Acute Myeloid Leukemia
- Hematologic Malignancies
Primary outcome
what the primary-completion date above is the date OFCompleteness and Yield of Multi-Modal Real-World Data Capture
measured Through study completion, up to 5 years
Permalink · TEM's whole pipeline · Catalyst calendar · Every registered study · What changed